Can vitamin a make a failed myeloma drug effective again?

NCT ID NCT06536413

Recruiting now Disease control Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a vitamin A derivative (ATRA) to a standard drug combination (carfilzomib and dexamethasone) can overcome resistance in multiple myeloma patients whose cancer no longer responds to carfilzomib. About 42 adults with relapsed/refractory myeloma will receive ATRA alongside their carfilzomib-based therapy. The goal is to see if the combination is safe and can shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: All-Trans Retinoic Acid (ATRA) combined with carfilzomib and dexamethasone
What this could lead to: If it works, this could offer a new treatment option for multiple myeloma patients whose cancer has become resistant to carfilzomib, potentially extending remission.
What could go wrong: This is an early-phase trial with only 42 participants, so results may not apply broadly. ATRA may not restore sensitivity in all patients, and side effects from the combination are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Houston Methodist Neal Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.